CGM Skin-Sensor Interface Patent Snapshot 2026
The CGM skin-sensor interface patent space is extremely nascent, with only 4 patent families on record and activity concentrated entirely in Indian academic institutions. The field shows early-stage emergence from 2023 onward, leaving the assignee snapshot effectively open for industrial and global entrants.
Indian Institute of Technology Madras holds virtually the entire Snapshot
Indian Institute of Technology Madras (IIT Madras) is the visible filer, holding 3 of the 4 patent families in scope. The only other active applicant is P S R Engineering College, with 1 patent family. Together they account for 100% of the top filers’ combined output.
Concentration is absolute: the top five filers among the ranked applicants visible in this query hold 100% of that group’s combined total, and both active applicants are Indian academic institutions. There is no visible tier of industrial or multinational challengers at this time.
| # | Applicant | Patent families | Share |
|---|---|---|---|
| 1 | Indian Institute of Technology Madras | 3 | |
| 2 | P S R Engineering College | 1 |
IIT Madras’s position as near-sole patent holder means it effectively defines the prior-art boundary for this sub-field. Any new entrant — industrial or academic — must design around or license from this single institution, or stake out genuinely differentiated technical ground.
The corpus of 4 patent families is small and recent; filings from 2024–2025 are subject to publication lag and the true count may be modestly higher than currently indexed. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Activity emerged only in 2023; diagnostic and drug-delivery classes dominate the technology mix
The filing trend and technology composition charts together reveal a field that is both very young and narrowly defined in IPC terms, with no recorded activity before 2023 and a small but consistent set of technology classes.
Annual filing trend
Zero filings were recorded from 2017 through 2022. Activity began in 2023 with 2 patent families, followed by 1 each in 2024 and 2025. The 2024–2025 figures are subject to publication lag and should be treated as lower bounds. The overall pattern indicates a field at inception rather than at scale.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61B (Diagnosis & surgery) and A61M (Devices for body fluids) each appear across all 4 patent families, confirming that current work sits at the intersection of biosensing and transdermal delivery. G16H (Healthcare informatics) appears in 1 family, suggesting early but limited interest in data-layer integration. No other IPC branches are represented, pointing to a technically narrow corpus.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
System and method to form continuous glucose monit…
Disclosed herein is a system (100) and method (500) to form a continuous glucose monitoring (CGM) device The system (100) includes a modular housing (106) that has a display unit (102). The system (100) further includes a continuous glucose monitoring (CGM) patch (112) that is removably disposed within the modular housing (106) and communicably coupled to… (excerpt from the patent abstract)
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
Assignee snapshot from the current evidence set
The applicants below are visible in this query result. Because the evidence set is relatively small, read this section as a directional snapshot rather than a full competitive ranking.
Indian Institute of Technology Madras
IIT Madras holds 3 patent families — all the A61B5 (biosensing) and A61M5 (fluid delivery) claims filed so far — and has also reached into G16H40 (healthcare informatics), indicating an ambition to cover the full sensor-to-data pipeline. Momentum is classified as a new entrant, consistent with activity beginning only in 2023. The PCT application (WO2025074375A1) signals intent to extend protection beyond India.
families: 3P S R Engineering College
P S R Engineering College holds 1 patent family, covering A61B5 (diagnosis), A61M37, and A61M5 (body-fluid devices). Its single family filed domestically in India positions it as a secondary academic participant rather than a strategic challenger. No momentum data beyond its single filing is available in the evidence.
families: 1Frequently asked questions
The evidence covers 4 patent families in scope globally. The corpus is very small and concentrated, with all activity recorded from 2023 onward.
Indian Institute of Technology Madras holds 3 patent families, making it the visible filer. P S R Engineering College holds the remaining 1 family. Both are Indian academic institutions; no commercial or multinational applicants appear in the current evidence.
India accounts for 3 of the patent records, with 1 filed via WIPO PCT. No US, European, Chinese, or other major market filings are recorded in the current corpus.
A61B (Diagnosis & surgery) and A61M (Devices for body fluids) each appear across all 4 patent families. G16H (Healthcare informatics) appears in 1 family. No other IPC branches are represented in the current evidence.
The field shows no activity from 2017 through 2022, then 2 families in 2023 and 1 each in 2024 and 2025. The 2024–2025 figures are subject to publication lag. The pattern indicates a field at inception rather than sustained growth, and a formal lifecycle stage classification is not yet supported by the evidence.
Electrochemical sensing methods (G01N) and wireless transmission classes (H04W, H04B) are entirely absent from the current corpus, despite being foundational to real-world CGM systems. Biocompatible adhesive interfaces and microneedle fabrication are also unrepresented. These are observations of sparsity in the current evidence and should be validated against the broader CGM patent literature before drawing investment conclusions.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.